Skip to content

Histone deacetylase as a potential therapeutic target for memory dysfunction during aging and neurodegenerative disorders.

2026 · Methods in Enzymology · Vol 733, pp. 279-295 · 0 citations
Medicine

TL;DR

Pharmacological inhibition of HDAC activity has been shown to restore histone acetylation levels, enhance the expression of neuroprotective genes, and improve synaptic plasticity in various experimental models.

View source

Similar papers

Review 2026

Epigenetic modulators as therapeutics for neurodegenerative disorders/Alzheimer's disease.

Overall, epigenetic modulators present a promising therapeutic approach for neurodegeneration, and continued research integrating various assays like DNA methylation analysis, histone modification analysis, non-coding RNA analysis, neuroinflammation analysis, and functional and behavioral assays in AD models is signifi...

Debojyoti Halder, Denish Prajapati, Tonmoy Banerjee et al. · 0 citations
Review 2026

The potential of HDAC inhibitors for Alzheimer's disease.

The chapter provides in-depth information on the role of HDAC inhibitors, which hold significant potential as disease-modifying agents in the treatment of Alzheimer's disease and explores various challenges such as off-target effects, restricted isoform specificity, and inadequate blood-brain barrier permeability.

Vedika Jain, S. Bharti · 0 citations
Review Open access Sep 2026

Isoform selective targeting of histone deacetylases as a precision therapeutic strategy for neurodegenerative diseases

Histone deacetylases (HDACs) are epigenetic enzymes that eliminate acetyl groups from histone lysine residues, promoting chromatin compaction and transcriptional repression. Dysregulation of HDAC activity is increasingly recognized as a central contributor to the pathogenesis of major neurodegenerative diseases, includ...

M. D. Olorunsesan, P. Oyedokun, Joshua Oluwasola Gbadero et al. · 0 citations
Review Open access Sep 2026

SIRT1 in Neurodegenerative Diseases: Molecular Mechanisms, Disease Relevance, and Therapeutic Potential

Neurodegenerative diseases are characterized by progressive protein aggregation, mitochondrial dysfunction, neuroinflammation, and cognitive decline, yet effective mechanism‐based interventions remain limited. Sirtuin 1 (SIRT1), an NAD+‐dependent deacetylase, has emerged as a multifunctional regulator linking stress ad...

Jia-Bin Duan, Jia-Qiang Liu, Qing-Sheng Meng et al. · 0 citations
Review Open access Sep 2026

RNA dysregulation as a determinant of aging and neurodegenerative vulnerability.

In the nervous system, aging causes deterioration of cellular and molecular processes that are associated with declines in cognition, sensory perception, and motor coordination. Aging is also the strongest risk factor for neurodegenerative disease, yet the mechanisms by which aging predisposes neurons to dysfunction re...

Sawyer Randles, Gene W. Yeo · 0 citations
Open access Aug 2026

Emerging Advances in Neuropharmacology: Novel Therapeutic Targets for Neurodegenerative Disorders

Neurodegenerative diseases are a heterogeneous group of chronic and progressive disorders, which are characterized by selective neuronal destruction, synaptic malfunction and progressive cognitive and locomotor dysfunction. The major ones are Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lat...

Nisha, Sumairah Qadir · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.